What Cellaviva does

Cellaviva AB is a Swedish tissue establishment and biobank founded in 2014 by researchers from Karolinska Institutet and headquartered in Huddinge, Sweden. The company operates as a wholly-owned subsidiary of NextCell Pharma AB, a public biotech focused on regenerative medicine and cell therapy. Cellaviva's core offering is the collection, processing, and long-term cryogenic storage of stem cells from umbilical cord blood, umbilical cord tissue, and placenta at birth, using a CE-marked medical device collection kit (the Cellavivabox) and ISO 15189/EFI-accredited laboratory partners. Mesenchymal stem cells from cord tissue are isolated and characterized rather than stored as raw tissue, with sterility and viability testing prior to cryopreservation. Storage is conducted under continuous monitoring in compliance with the EU tissue directive, Swedish biobankslagen, GDPR, and IVO supervision (biobank registration number 932).

The company's business model combines one-time transactional revenue (stem cell collection and genetic tests priced 3,700-8,000 SEK each) with recurring annual cryogenic storage subscriptions, sold direct-to-consumer via its own e-commerce site (www.cellaviva.se) with home-delivered test kits and digital contract signing. Since 2024, Cellaviva has expanded into genetic health testing with the launch of Transplant Match HLA (transplant compatibility), Cellaviva Fertility Insight (55-gene female, 40-gene male, and thrombophilia/NAIT panels), and Celiac Risk & Genetic Analysis, all based on saliva or cheek swab samples analyzed via NGS. A comprehensive whole-genome NIPT is slated for 2026. Through its membership in the FamiCord Group, Europe's largest family stem cell banking network, Cellaviva gains access to 1,500+ partner hospitals and clinics, 15+ laboratories, 1M+ stored samples, and the FamiCord Expanded Access Protocol for cord blood therapy in cerebral palsy and autism. Primary customers are expecting families (stem cell banking), individuals and couples with fertility challenges, families with transplant needs, and individuals seeking celiac or health risk genetic insights.

Name

Cellaviva

Legal name

Cellaviva AB

Website

https://cellaviva.se

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Cellaviva is a Swedish biobank and DTC genetic health platform offering cord blood/tissue stem cell banking plus NGS-based genetic tests (HLA, fertility, celiac), serving expecting families and consumers across Sweden and the EU.

Ownership category

akta.pro rank

Headquarters

HQ city

Huddinge

HQ country

Sweden

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Stem Cell Banking Services: One-time collection, processing, analysis, and cryopreservation of stem cells from cord blood, cord tissue, and placenta at birth, with ongoing long-term storage fees. Recurring annual storage fees apply for the storage period selected by the family.
2. Genetic and Health Testing: One-time fees for genetic tests including Transplant Match HLA (8,000 SEK), Celiac Risk & Genetic Analysis (3,700 SEK), and Fertility Insight panels. These are discrete, per-test transactions with no recurring obligation.
3. Storage Subscription: Ongoing annual or multi-year cryogenic storage fees for preserved stem cells, billed periodically according to the customer's selected storage plan.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Cellaviva provides family stem cell banking services, collecting, processing, characterizing, and cryopreserving stem cells from umbilical cord blood, cord tissue, and placenta at birth, then storing the samples long-term under continuous monitoring. The company complements this with NGS-based genetic health tests, including high-resolution HLA typing for transplant compatibility, fertility genetic panels, and HLA-DQ2/DQ8 celiac risk genotyping, all delivered through a direct-to-consumer model with at-home sample collection. Operations are conducted in ISO 15189/EFI-accredited laboratories under IVO supervision as a licensed Swedish tissue establishment and registered biobank.

Product overview

Cellaviva offers a biobanking and genetic testing platform built around stem cell preservation services and health genetic tests. The core offering is the Cellavivabox, a CE-marked medical device collection kit that enables families to preserve stem cells from three sources at birth: umbilical cord blood (hematopoietic stem cells), umbilical cord tissue (mesenchymal stem cells), and placenta tissue. These biological samples are processed, analyzed, and stored long-term in cryogenic facilities. Complementing the stem cell banking service, Cellaviva provides genetic health tests including Transplant Match HLA (for transplant compatibility), Cellaviva Fertility Insight (female/male fertility genetic panels), and Celiac Risk & Genetic Analysis (HLA-based celiac predisposition testing). An upcoming comprehensive NIPT whole genome analysis test is also in development.

Differentiator

Problem solved

Functional benefit

Products and services

• Stamcellssparande (Stem Cell Banking) Core service for collecting, processing, characterizing (with sterility and viability testing), and long-term cryogenic storage of stem cells from umbilical cord blood, umbilical cord tissue, and placenta collected at birth, intended for expecting families seeking biological insurance for potential future medical treatments.
• Cellavivabox (Collection Kit) CE-marked medical device collection kit (compliant with EU MDR 2017/745) containing sterile equipment, transport materials, and instructions used by trained personnel at partner hospitals to collect cord blood and/or cord tissue from the placenta during childbirth for subsequent Cellaviva processing and storage.
• Transplant Match HLA (Transplantationsmatch HLA) Genetic test that uses NGS to perform high-resolution six-digit HLA typing (HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DPB1) for adults and families seeking to determine donor-recipient compatibility for stem cell, bone marrow, or organ transplantation; offered via home cheek swab or priority in-clinic collection at Cellaviva's Huddinge facility.
• Cellaviva Fertilitetsinsikt (Fertility Insight) Saliva-based genetic test using next-generation sequencing to analyze fertility-related genetic variants in individuals or couples, with a 55-gene female fertility panel, a 40-gene (+ sex chromosomes) male fertility panel, and an optional 22-variant thrombophilia & NAIT add-on; intended for those with unexplained infertility, recurrent miscarriage, or planning assisted reproductive technology.
• Celiakirisk & Genetisk Analys (Celiac Risk & Genetic Analysis) Saliva-based genetic test that uses HLA typing to identify HLA-DQ2 and HLA-DQ8 variants associated with celiac disease risk, providing genetic predisposition information without requiring prior gluten exposure or invasive biopsy; intended for adults and children with suspected gluten-related symptoms, family history of celiac disease, or inconclusive standard testing.

Quantifiable outcome

• 85,000+ cord blood transplants performed globally; used in >80 malignant and non-malignant conditions
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core, strategic and minor.

• FamiCord GroupcoreStrategic or Co-development PartnerCellaviva is a member of the FamiCord Group, Europe's largest family stem cell banking network. The network comprises 15+ laboratories and storage locations, 1,500+ partner hospitals and clinics, and has stored 1 million+ stem cell samples. Through this network, Cellaviva offers families access to the FamiCord Group Expanded Access Protocol for Cord Blood in Brain Development — a programme for children with cerebral palsy or autism spectrum disorder who have their own cord blood stored — providing access to investigational cord blood therapy outside traditional clinical trials.
• Professor Magdalena Chrościńska-Krawczyk (University Children's Hospital, Lublin)coreImplementation/ SI/ Consulting PartnerProfessor Magdalena Chrościńska-Krawczyk, a pediatric neurologist at the University Children's Hospital in Lublin, is a lead clinical partner in the FamiCord Group Expanded Access Programme for cord blood therapy in cerebral palsy and autism. She leads the clinical evaluation and treatment of eligible children within the programme.
• Professor Joanne Kurtzberg / Duke UniversitystrategicStrategic or Co-development PartnerProfessor Joanne Kurtzberg and her team at Duke University pioneered much of the clinical research into cord blood use for neurological conditions including cerebral palsy and autism. This foundational research underpins the FamiCord Group Expanded Access Programme in which Cellaviva participates, enabling eligible families to access cord blood therapies.
• FamiCord Group Partner Hospitals and ClinicscoreChannel Partner/ Reseller/ DistributorThe FamiCord Group network includes 1,500+ partner hospitals and clinics across Europe that work with Cellaviva member biobanks for stem cell collection at birth. Midwives and obstetric staff at these facilities use the Cellaviva Box to collect cord blood, cord tissue, and placenta samples for processing and storage.
• ISO 15189 / EFI Accredited Laboratory PartnerscoreTechnology or IntegrationHLA typing for Transplant Match testing is performed by laboratories accredited according to ISO 15189, accredited by the European Federation for Immunogenetics (EFI), and operating in accordance with GMP guidelines. Fertility and celiac genetic tests are analyzed by accredited laboratory partners using next-generation sequencing (NGS). Results meet international quality and regulatory standards and are recognized by healthcare providers and transplantation centres throughout Europe.
• DHL, PostNord, Best Transport, and Other Logistics PartnersminorChannel Partner/ Reseller/ DistributorCellaviva uses multiple logistics partners including DHL, PostNord, Best Transport, and other courier and express delivery providers for the delivery of collection kits and genetic test kits to customers. Partner selection is individualized based on customer location, delivery urgency, product sensitivity, and cost.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• NextCell Pharma AB: NextCell Pharma AB is Cellaviva's publicly listed parent company, developing stem cell therapies (ProTrans) using MSCs derived from umbilical cord tissue — the same biological source Cellaviva banks. Closely comparable on underlying biology and regulatory environment, and a key channel for translating banked samples into future approved therapies.
• Smart Cells International: UK-headquartered cord blood and tissue banking service operating worldwide with home-collection kits and long-term cryogenic storage. Closely comparable on DTC consumer biobank offering, geographic scope (EU + international), and recurring storage revenue model.
• Biovault Family: European private cord blood bank with HTA-licensed storage in the UK, offering cord blood and tissue processing and cryopreservation. Comparable on regulatory-quality positioning, clinical processing protocols, and DTC model aimed at expecting families.
• Cells4Life: UK-based private stem cell bank offering cord blood and cord tissue collection with multi-year storage plans. Directly comparable DTC consumer biobank model in Europe, competing for cross-border EU families and using a similar cryogenic storage / annual subscription structure.

Broad incumbents

• FamiCord Group: FamiCord Group is Europe's largest family stem cell banking network and Cellaviva's parent network. Cellaviva operates as a member biobank under FamiCord, sharing the same cord blood/tissue banking model, FamiCord Box collection kits, and the Expanded Access Protocol for cerebral palsy and autism. Most directly comparable on product, model, and infrastructure footprint (15+ labs, 1M+ stored samples).
• Cordlife Group: Asia-Pacific-focused publicly listed cord blood banking group with operations across Singapore, Hong Kong, India, Indonesia, Malaysia, and the Philippines. Comparable on consumer biobank model and recurring storage revenue, though geographically focused outside Cellaviva's core EU market.
• StemCyte: US-based hybrid public-private cord blood bank combining family storage with a significant public banking registry supplying transplants worldwide. Comparable on biological materials, processing standards, and HLA typing services relevant to Cellaviva's Transplant Match offering.
• Cryo-Cell International: US-based publicly listed family cord blood bank and one of the longest-operating consumer biobanks. Comparable on DTC cord blood + cord tissue storage model, multi-year subscription pricing, and accredited laboratory processing — though operating in a different regulatory environment.
• ViaCord: Established US family cord blood bank (a Revvity subsidiary) offering cord blood and tissue banking with multi-year storage plans. Comparable on consumer brand, premium positioning, recurring storage model, and integration with broader reproductive/genetic health services from its parent.

Emerging players

• Natera: US-listed clinical genetic testing company offering reproductive and oncology genetic tests including non-invasive prenatal testing (NIPT) and carrier screening. Comparable on the genetic testing side of Cellaviva's portfolio — particularly its Cellaviva Fertility Insight panels and upcoming comprehensive NIPT — though Natera is the broader clinical/enterprise incumbent Cellaviva would compete against for prenatal genetic share.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/cellaviva
• Facebookfacebook.com/cellavivasverige
• LinkedInlinkedin.com/company/cellaviva-ab

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellaviva